These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 27912207)

  • 1. Clinical Adverse Effects of Endothelin Receptor Antagonists: Insights From the Meta-Analysis of 4894 Patients From 24 Randomized Double-Blind Placebo-Controlled Clinical Trials.
    Wei A; Gu Z; Li J; Liu X; Wu X; Han Y; Pu J
    J Am Heart Assoc; 2016 Oct; 5(11):. PubMed ID: 27912207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A network meta-analysis for safety of endothelin receptor antagonists in pulmonary arterial hypertension.
    Zhang YJ; Wang N; Gu ZC; Wei AH; Cheng AN; Fang SS; Du HL; Wang LZ; Zhang GQ
    Cardiovasc Diagn Ther; 2019 Jun; 9(3):239-249. PubMed ID: 31275814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy and safety of endothelin receptor antagonists combined with phosphodiesterase 5 inhibitor in the treatment of pulmonary arterial hypertension: a network meta-analysis].
    Fu WH; Chen PL; Xia JL; Fu L; Shen Y; He WJ; Chen YH; Ren N; Jiang Q; Ma R; Wang T; Wang XN; Zhang NF; Liu CL
    Zhonghua Jie He He Hu Xi Za Zhi; 2022 Feb; 45(2):158-170. PubMed ID: 35135085
    [No Abstract]   [Full Text] [Related]  

  • 4. [Hepatotoxicity in patients treated with endothelin receptor antagonists: systematic review and meta-analysis of randomized clinical trials].
    Macías Saint-Gerons D; de la Fuente Honrubia C; Montero Corominas D; Catalá-López F
    Med Clin (Barc); 2014 Apr; 142(8):333-42. PubMed ID: 23540381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells.
    Gatfield J; Mueller Grandjean C; Sasse T; Clozel M; Nayler O
    PLoS One; 2012; 7(10):e47662. PubMed ID: 23077657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of oral endothelin receptor antagonists with risks of cardiovascular events and mortality: meta-analysis of randomized controlled trials.
    Pan Y; Hu C; Chen PH; Gu YH; Qiao QY; Pan LH; Zhou DC; Gu HF; Fu SK; Jin HM
    Eur J Clin Pharmacol; 2017 Mar; 73(3):267-278. PubMed ID: 27957707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative adherence of macitentan versus ambrisentan and bosentan in Australian patients with pulmonary arterial hypertension: a retrospective real-world database study.
    Lau E; Kotlyar E; Makanji Y; Yu DY; Tan JY; Casorso J; Kouhkamari MH; Lim S; Wu DB; Bloomfield P
    J Med Econ; 2024; 27(1):596-604. PubMed ID: 38488130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endothelin receptor antagonists for persistent pulmonary hypertension in term and late preterm infants.
    More K; Athalye-Jape GK; Rao SC; Patole SK
    Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD010531. PubMed ID: 27535894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative assessment of efficacy and safety of ambrisentan and bosentan in patients with pulmonary arterial hypertension: A meta-analysis.
    Zhao Q; Guo N; Chen J; Parks D; Tian Z
    J Clin Pharm Ther; 2022 Feb; 47(2):146-156. PubMed ID: 34319626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver injury due to endothelin receptor antagonists: a real-world study based on post-marketing drug monitoring data.
    Dong S; Guo X; Wang H; Sun C
    Ther Adv Respir Dis; 2024; 18():17534666231223606. PubMed ID: 38179676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative safety and tolerability of endothelin receptor antagonists in pulmonary arterial hypertension.
    Aversa M; Porter S; Granton J
    Drug Saf; 2015 May; 38(5):419-35. PubMed ID: 25792028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the endothelin receptor antagonists ambrisentan, bosentan, macitentan, and sitaxsentan as hepatobiliary transporter inhibitors and substrates in sandwich-cultured human hepatocytes.
    Lepist EI; Gillies H; Smith W; Hao J; Hubert C; St Claire RL; Brouwer KR; Ray AS
    PLoS One; 2014; 9(1):e87548. PubMed ID: 24498134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis.
    Dranitsaris G; Mehta S
    Appl Health Econ Health Policy; 2009; 7(1):43-59. PubMed ID: 19558194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Focus on Macitentan in the Treatment of Pulmonary Arterial Hypertension.
    Bedan M; Grimm D; Wehland M; Simonsen U; Infanger M; Krüger M
    Basic Clin Pharmacol Toxicol; 2018 Aug; 123(2):103-113. PubMed ID: 29719121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy and acceptability of endothelin receptor antagonists for pulmonary arterial hypertension: A network meta-analysis.
    Duo-Ji MM; Long ZW
    Int J Cardiol; 2017 May; 234():90-98. PubMed ID: 28233631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic Review of Randomized Controlled Trials of Endothelin Receptor Antagonists for Pulmonary Arterial Hypertension.
    Kuntz M; Leiva-Juarez MM; Luthra S
    Lung; 2016 Oct; 194(5):723-32. PubMed ID: 27506903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Treatment Persistence and Adherence to Endothelin Receptor Antagonists Among Patients with Pulmonary Arterial Hypertension in Japan: A Real-World Administrative Claims Database Study.
    Omura J; Makanji Y; Tanabe N; Yu DY; Tan JY; Lim S; Kouhkamari MH; Casorso J; Wu DB; Bloomfield P
    Pulm Ther; 2023 Dec; 9(4):511-526. PubMed ID: 37991630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of switching from bosentan or ambrisentan to macitentan in pulmonary arterial hypertension: A systematic review and meta-analysis.
    Li J; Yang ZY; Wang S; Yuan P; Zhao QH; Gong SG; Qiu HL; Luo CJ; Li HT; Zhang R; Wu WH; Liu JM; Wang L; Liu SS; Jiang R
    Front Cardiovasc Med; 2022; 9():977110. PubMed ID: 36568539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Clinical Efficacy of Endothelin Receptor Antagonists in Patients with Pulmonary Arterial Hypertension.
    Maki H; Hara T; Tsuji M; Saito A; Minatsuki S; Inaba T; Amiya E; Hosoya Y; Hatano M; Morita H; Yao A; Kinugawa K; Komuro I
    Int Heart J; 2020; 61(4):799-805. PubMed ID: 32728000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.